ChristopherThomasda CostaMDPhD, MBA, FACP, FIDSA, CWSP, CPE

Hospital Medicine/Hospitalist, Preventive Medicine, Infectious Disease

Physician-scientist, Immunologist, Internal Medicine, infectious Diseases, Wound Care, Hyperbaric Medicine, Vaccine development, Therapeutic and Immunoprophylactic drug development. Takemi Fellow in International Health. Harvard T. H. Chan School of Public Health.

Join to view full profile

Dr. da Costa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. da Costa's full profile

Already have an account?

Office
Furlong
Furlong, PA 18925
Phone+1 267-406-2485
Is this information wrong?

Summary

US licensed and board-certified physician with over 20 years' experience in clinical medicine and over 15 years total of clinical and basic science research experience, including phase I-IV clinical development, medical affairs, health economics & outcomes research, regulatory affairs, and strategic leadership of clinical development teams. Expertise spans vaccine and small molecule clinical research and development, including efficacy, safety, and effectiveness studies for prophylactic pediatric vaccines, as well as expertise in strategic development planning in therapeutic vaccinology, including monoclonal antibody-based active and passive immunotherapy. Therapeutic area experience includes vaccines, infectious diseases, neuroscience, hematology, organ transplantation, and immunology. Clinical experience includes internal medicine, infectious diseases, wound care/ esthetic and hyperbaric medicine. Fellow American College of Physicians, Fellow Infectious Disease Society of America. Certified Wound Specialist Physician. Dr. da Costa was appointed to the staff of the Harvard T.H. Chan School of Public Health in August 2023 as a Takemi International Health Fellow.

Education & Training

Harvard School of Public HealthTakemi Fellow in International Health, Takemi International Health Fellowship, 2023 - 2024
Harvard Medical SchoolGlobal Health, Global Health Care Leaders Program, 2021 - 2022
Wharton School, University of PennsylvaniaEntrepreneurial Acceleration Program, Executive education (Business), 2019 - 2019
Auburn UniversityMBA, Physician's Executive MBA, 2001 - 2003
Kirk Kerkorian School of Medicine at UNLVChief Residency, Internal Medicine, 1998 - 1999
Kirk Kerkorian School of Medicine at UNLVResidency, Internal Medicine, 1996 - 1998
London School of Hygiene & Tropical MedicinePhD, Immunology (Infectious Diseases), 1987 - 1991
London School of Hygiene & Tropical MedicineMSc., Clinical Tropical Medicine, 1985 - 1986
University of Zambia, School of MedClass of 1983

Certifications & Licensure

FL State Medical License 2018 - 2026
PA State Medical License 2007 - 2024
VA State Medical License 2000 - 2016
NC State Medical License 2011 - 2016
CA State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine
AAPLCertification in Medical Management (CPE)
American Board of Wound ManagementCertified Wound Specialist Physician

Awards, Honors, & Recognition

Fellow American College of Physicians
Fellow Infectious Disease Society of America
Best Internal Medicine Resident, Ambulatory Clinic University of Nevada School of Medicine, 1998-1999
Pfizer (UK) Academic Travel Award Pfizer, 1994
Association of Clinical Pathology (UK) Travel Award Association of Clinical Pathology (UK), 1994
Beit Memorial Medical Research Fellowship Beit Trust, 1987-1991
Join now to see all

Clinical Trials

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease Start of enrollment: 2007 May 01
Completed
Phase 2
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease Start of enrollment: 2007 Nov 01
Completed
Phase 2
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Start of enrollment: 2007 Nov 20
Completed
Phase 2
The Effectiveness of Varicella Vaccination in Children in Germany Start of enrollment: 2008 Feb 01
Completed
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab Start of enrollment: 2009 Jun 01
Terminated
Phase 2
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease Start of enrollment: 2009 Jul 01
Terminated
Phase 3
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease Start of enrollment: 2009 Nov 05
Completed
Phase 2
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease Start of enrollment: 2009 Jul 01
Terminated
Phase 2
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease Start of enrollment: 2011 Feb 01
Completed
Phase 2
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease Start of enrollment: 2010 Dec 01
Completed
Phase 2
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease Start of enrollment: 2011 Jan 01
Completed
Phase 2
Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients Start of enrollment: 2011 May 01
Completed
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin Start of enrollment: 2008 Nov 01
Completed
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Start of enrollment: 2012 Oct 29
Completed
Phase 3
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI Start of enrollment: 2015 Oct 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
End of the Bedaquiline patent - a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income ...
Eskild Petersen, David S Hui, Jean B Nachega, Francine Ntoumi, Delia Goletti, Eleni Aklillu, Avinash Sharma, Thomas Nyirenda, Dorothy Yeboah-Manu, Giovanni Satta, Chri...> ;International Journal of Infectious Diseases. 2023 Jun 1
2 citations
Advances in development of new tuberculosis vaccines.
Christopher da Costa, Philip Onyebujoh, Georges Thiry, Alimuddin Zumla> ;Current Opinion in Pulmonary Medicine. 2023 May 1
2 citations
COVID-19 risk perception, cognitive dissonance, and vaccine hesitancy.
Ozlem Equils, Amonda Bakaj Berishaj, Eric Stice, Christopher da Costa> ;Human Vaccines & Immunotherapeutics. 2023 Dec 31
27 citations
Addressing and Inspiring Vaccine Confidence in Black, Indigenous, and People of Color During the Coronavirus Disease 2019 Pandemic.
Jasmine R Marcelin, Talia H. Swartz, Fidelia Bernice, Vladimir Berthaud, Robbie Christian, Christopher da Costa, Nada Fadul, Michelle Floris-Moore, Matifadza Hlatshway...> ;Open Forum Infectious Diseases. 2021 Aug 9
13 citations
The effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus : data from a prospective doubl...
Ozlem Equils, Christopher da Costa, Michele Wible, Benjamin A. Lipsky> ;BMC Infectious Diseases. 2016 Sep 6
3 citations
Sepsis 2016 Agra, India
Surinder Kumar Sharma, Anurag Rohatgi, Mansi Bajaj, Charles L. Sprung, Ricardo Calderon morales, Harvey Kasdan, Allon Reiter, Tobias Volker, Julien Meissonnier, Natali...> ;Critical Care. 2016 Mar 2
Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.
Mufson, M. A.,Diaz, C.,Leonardi, M.,Harrison, C. J.,Grogg, S.,Carbayo, A.,Carlo-Torres, S.,JeanFreau, R.,Quintero-Del-Rio, A.,Bautista, G.,Povey, M.,Da Costa, C.,Nicho...> ;J Pediatric Infect Dis Soc. 2015 Nov 20
37 citations
Tuberculosis vaccines--state of the art, and novel approaches to vaccine development.
Christopher da Costa, Barry Walker, Aurelio Bonavia> ;International Journal of Infectious Diseases. 2015 Mar 1
23 citations
Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to child...
Mark M. Blatter, Nicola P. Klein, Julie Shepard, Michael Leonardi, Steven Shapiro, Martin Schear, Maurice A. Mufson, Judith M. Martin, Meera Varman, Stanley E. Grogg, ...> ;The Pediatric Infectious Disease Journal. 2012 Aug 1
38 citations
Diarrhea: Case definition and guidelines for collection, analysis, and presentation of immunization safety data
Jane Gidudu, David A. Sack, M. Pina, Michael J. Hudson, Katrin S. Kohl, Phyllis R. Bishop, Arani Chatterjee, Elena Chiappini, A. Compingbutra, C. da Costa, R Fernandop...> ;Vaccine. 2011 Jan 29
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.
Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law...> ;Vaccine. 2010-06-18
A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, Hoet B, Rothstein E, Schuind A, Varricchio F, Walop W> ;Vaccine. 2008 Dec 09
33 citations
Immunoglobulin G subclass responses to mycobacterial lipoarabinomannan in HIV-infected and non-infected patients with tuberculosis.
C. T. K. A. Da Costa, S. Khanolkar-Young, Alison M. Elliott, K. M. A. Wasunna, K. P. W. J. Mcadam> ;Clinical and Experimental Immunology. 2008 Jun 28
20 citations
Empyema thoracis and lung abscess due to Gemella morbillorum.
C. T. K. A. da Costa, C. Porter, K. Parry, A. Morris, A. H. Quoraishi> ;European Journal of Clinical Microbiology & Infectious Diseases. 1996 Jan 1
17 citations
An investigation of a nosocomial outbreak of Clostridium difficile by pyrolysis mass spectrometry.
J. T. Magee, Jon S. Brazier, I.K. Hosein, C. D. Ribeiro, D. W. Hill, A. Griffiths, C. Da Costa, A. J. Sinclair, B. I. Duerden> ;Journal of Medical Microbiology. 1993 Nov 1
Join now to see all

Journal Articles

Perspectives on Advancement and Development of Tuberculosis Vaccines
Christopher da Costa, Christine S. Benn, Thomas Nyirenda, Evans Mpabalwani, Harleen M.S. Grewal, Rizwan Ahmed, Nathan Kapata, Peter S. Nyasulu, Markus Maeurer, David S..., International Journal of Infectious DIseases, 2/25/2024
End of the Bedaquiline patent – a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income ...
Eskild Petersen, David S. Hui, Jean B. Nachega, Francine Ntoumi, Delia Goletti, Eleni Aklillu, Avinash Sharma, Thomas Nyirenda, Dorothy Yeboah-Manu, Giovanni Satta, Ch..., International Journal of Infectious DIseases, 4/6/2023
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
John Kokai-Kun, PhD, Tracey Roberts, BSN, Olivia Coughlin, PhD, Heidi Whalen, MHS, Charles Le, PhD, Christopher Da Costa, MD, PhD and Joseph Sliman, MD, PhD, Open Forum Infect Dis. 2017 Fall; 4(Suppl 1): S12. Published online 2017 Oct 4. doi: 10.1093/ofid/ofx162.029 PMCID: PMC5631845, 2017
Anti-C3d neoantigen-based immune complex ELISA assays for diagnostic and immunopathogenetic investigation of HIV-associated tuberculosis
da Costa, C, http://www.sciencedirect.com/science/article/pii/0888078694900108, 9/1/1994
Join now to see all

Books/Book Chapters

New Topics in Vaccine Development
Chapter: Supply Chain Logistics and Business Ecosystems Needed for the Development of Natural Vaccines with Novel, Safer, and Noninvasive Delivery Mechanisms
Dawson Dodds, John W. Kindt Jr, Christopher da Costa, Nazmul Kazi, Joseph T. Mahoney and S. Indu RupassaraEditors: Mourad Aribi.IntechOpen2023
New Topics in Vaccine Development
Chapter: Perspective Chapter: Natural adjuvants for mucosal vaccines - The promise of tomatine as an inherent adjuvant in tomatoes.
Nazmul Kazi, John W. Kindt Jr, Indika Kahanda, Christopher da Costa, Robert Carnahan, Hugh Mason, Brenda A. Wilson and S. Indu RupassaraIntechOpen2023
New Topics in Vaccine Development
Chapter: Perspective Chapter: The Most Natural Possible Vaccine Administered in the Most Natural Possible Way - Noninvasive over Injectable Vaccine Delivery Routes
John W. Kindt Jr, Nazmul Kazi, Indika Kahanda, Christopher da Costa, Robert Carnahan, Brenda A. Wilson, Hugh Mason and S. Indu RupassaraEditors: Mourad Aribi.IntechOpen2023
Tuberculosis vaccines: Historical Perspectives on Tuberculosis Prevention and Novel Approaches to Vaccine Development
da Costa, CSM Group, Dover, DEEdition 1st,2016
Join now to see all

Abstracts/Posters

Immunogenicity of GlaxoSmithKline Biologicals, MMR Vaccine vs M-M-R® II, when Co-administered with Hepatitis A, Varicella and Pneumococcal Conjugate Vaccines to Toddle...
da Costa, C, https://idsa.confex.com/idsa/2011/webprogram/Paper31923.html, 10/21/2011
Efficacy of Two-dose MMRV and One-dose Varicella Vaccination in Children Aged 12-22 Months in 10 European Countries
da Costa, C, http://www.kenes.com/espid2010/posters/Abstract619.htm, 5/4/2010
Immunogenicity of one dose of Varicella vaccine and two doses of MMRV vaccine.
da Costa, C, http://www.kenes.com/espid2010/posters/Abstract558.htm, 5/4/2010
Immunogenicity and Safety of GSK Biologicals' MMRV Vaccine versus ProQuad® (Merck) When Co-Administered with Hepatitis A and Pneumococcal Conjugate Vaccines to Childre...
da Costa, C, http://www.nfid.org/professional-education/archives/acvr/acvr10.pdf, 4/26/2010
Antibody responses to recombinant 38kDa protein of Mycobacterium tuberculosis in HIV-infected and non HIV-infected tuberculosis patients.
da Costa, C, http://www.aegis.org/DisplayContent/print.aspx?SectionID=267135, 8/7/1994
Join now to see all

Lectures

Strengthening local supply chains, manufacturing & innovation for novel vaccines
University of Miami Global Health Program - 2/27/2024
CEPI: New vaccines for a safer world
Massachussetts General Hospital/Harvard University - 10/2/2023
COVID-19 – New Variants and Long COVID
National Medical Assocociation- Task Force on Vaccines and Therpeutics - 2/4/2023
Urosepsis
Asahi Kasei Pharma America boot camp, French Lick, IN - 10/2015
Safety of Recombinant Thrombomodulin
Asahi Kasei Pharma America boot camp, French Lick, IN - 10/2015
Recombinant Soluble Thrombomodulin in Severe Sepsis with Coagulopathy: Case studies. Investigator Meeting. Asahi Kasei Pharma America.
Chicago, IL - 10/2015
Tuberculosis: infection control in health care settings.
Inovio Pharmaceuticals, Philadelphia, PA - 11/1/2014
Tuberculosis vaccines: novel approaches to vaccine development and state of the art of clinical development.
Inovio Pharmaceuticals. Philadelphia, PA - 11/2014
Join now to see all

Other

Making the transition from clinical medicine to the pharmaceutical industry – Perspectives from real world experiences of a physician
Christopher da Costa
http://www.rxeconsult.com/healthcare-articles/From-Clinical-Medicine-to-Pharmaceutical-Industry---Physician-Experience-274/
2/3/2013
From Physician Practice to Pharmaceutical Industry Career
Christopher da Costa
http://www.rxeconsult.com/healthcare-articles/From-Physician-Practice-to-Pharmaceutical-Industry-Career-273/
2/1/2013

Authored Content

Advances in Development of New Tuberculosis VaccinesMay 2023

Press Mentions

Mentoring the Future of Health: An Evening with Dr. Chris Da Costa & Dr. Monica SoniOctober 18th, 2016
COVID-19 Alumni Stories: Christopher da CostaJuly 19th, 2020

Grant Support

Research Initiative Fund GrantUniversity of Wales College of Medicine1993–1995
Beit Memorial Medical Research Fellowship GrantBeit Trust1987–1991

Research History

Physician Reviewer (Consultant)Physician Reviewer for FDA Biologics Safety and Effectiveness Program for Vaccine and Blood Transfusion Products2019 - Present
Consultant, Vedanta BiosciencesMIcrobiome Therapeutics for the prevention of recurrent Clostridium difficile Infection, using Bacterial Consortia2018 - 2019
Consultant, Intarcia Therapeutics, Boston, MAClinical Development and Pharmacovigilance for a Drug-Device combination product for use in Glycemic Control in Diabetes Mellitus.2018 - 2019
Vice President of Clinical Development, Synthetic BiologicsClinical research and development of a first-in-class agent for the prevention of Clostridium difficile infection, and of a novel therapy for Irritable Bowel Syndrome with constipation (IBS-C).2017 - 2017
Global Medical Director, Asahi Kasei Pharma AmericaClinical development of recombinant thrombomodulin as a novel therapy for patients with sepsis, and for the prevention of early allograft dysfunction in liver transplant patients.2015 - 2017
Director of Clinical Development, Tuberculosis Vaccines, AerasClinical research and development of TB vaccines.2014 - 2015
Senior Medical Director, Pfizer Infectious DiseasesPhase IV clinical research on antibiotics Vancomycin and Linezolid.2011 - 2013
Compound Development Team Leader, Janssen Alzheimer Immunotherapy R&D, LLCClinical research on active and passive Immunotherapy for Alzheimer's disease.2010 - 2011
Director, Clinical Development and Medical Affairs, GlaxoSmithKline VaccinesClinical research and development of MMR and Varicella vaccines.2006 - 2010
Associate Director, Worldwide Regulatory Affairs, Merck and Co.Clinical research on Measles, Mumps, Rubella and Varicella vaccines.2005 - 2006
Clinical Lecturer and Research Fellow in Tropical MedicineResearch on immunology of tuberculosis in the context of HIV infection, at the London School of Hygiene & Tropical Medicine.1987 - 1991

Professional Memberships

American Association for Physician Leadership - AAPL
Certified Physician Executive (CPE)
American College of Physicians - ACP
Fellow
Infectious Disease Society of America - IDSA
Fellow
American Board of Wound Management
Certified Wound Specialist Physician
Pennsylvania Medical Society
Member
Bucks County Medical Society
Member
Florida Medical Association
Member